- Home
- RIV vs CRGX Comparison
RIV vs CRGX Comparison
Compare RIV & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- CRGX
- Stock Information
- Founded
- RIV 2015
- CRGX 2021
- Country
- RIV United States
- CRGX United States
- Employees
- RIV N/A
- CRGX N/A
- Industry
- RIV Finance Companies
- CRGX
- Sector
- RIV Finance
- CRGX
- Exchange
- RIV Nasdaq
- CRGX Nasdaq
- Market Cap
- RIV 258.1M
- CRGX 207.5M
- IPO Year
- RIV N/A
- CRGX 2023
- Fundamental
- Price
- RIV $12.36
- CRGX $4.54
- Analyst Decision
- RIV
- CRGX Hold
- Analyst Count
- RIV 0
- CRGX 7
- Target Price
- RIV N/A
- CRGX $5.33
- AVG Volume (30 Days)
- RIV 87.6K
- CRGX 1.7M
- Earning Date
- RIV 01-01-0001
- CRGX 08-06-2025
- Dividend Yield
- RIV 12.85%
- CRGX N/A
- EPS Growth
- RIV N/A
- CRGX N/A
- EPS
- RIV N/A
- CRGX N/A
- Revenue
- RIV N/A
- CRGX N/A
- Revenue This Year
- RIV N/A
- CRGX N/A
- Revenue Next Year
- RIV N/A
- CRGX N/A
- P/E Ratio
- RIV N/A
- CRGX N/A
- Revenue Growth
- RIV N/A
- CRGX N/A
- 52 Week Low
- RIV $9.63
- CRGX $3.00
- 52 Week High
- RIV $12.43
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- RIV 53.36
- CRGX 59.56
- Support Level
- RIV $12.20
- CRGX $4.45
- Resistance Level
- RIV $12.54
- CRGX $4.51
- Average True Range (ATR)
- RIV 0.11
- CRGX 0.04
- MACD
- RIV 0.00
- CRGX -0.00
- Stochastic Oscillator
- RIV 48.72
- CRGX 76.00
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.